Sage Journals: Discover world-class research

Abstract

Purpose

The pharmacology, pharmacokinetics, clinical trials, adverse effects, dosage recommendations, and economic considerations of carfilzomib are reviewed.

Summary

Multiple myeloma accounts for approximately 10–15% of all hematologic malignancies and 20% of blood‐related cancer deaths. Despite recent advances in the treatment of multiple myeloma, most patients will eventually relapse, requiring further treatment. Carfilzomib is a new proteasome inhibitor that primarily targets the chymotrypsin‐like activity of the 20S proteasome. The safety and efficacy of carfilzomib was demonstrated in the PX‐171‐003‐A1 trial, a prospective phase II trial in patients with relapsed or refractory multiple myeloma who had received at least 2 prior therapies including a proteasome inhibitor and an immunomodulatory agent. Common adverse effects included fatigue (55.5%), anemia (46.8%), nausea (44.9%), and thrombocytopenia (36.3%). The recommended dose of carfilzomib for the first cycle is 20 mg/m² on 2 consecutive days each week for 3 weeks in a 4‐week cycle escalating to 27 mg/m² for subsequent cycles. It is recommended that patients receive premedication with dexamethasone during cycle 1 and cycle 2 to minimize risk of infusion reactions.

Conclusion

Carfilzomib provides a clinical benefit to patients with relapsed or refractory multiple myeloma who have been previously treated with a proteasome inhibitor and an immunomodulatory agent.

Keywords

Carfilzomib kyprolis multiple myeloma proteasome inhibitor PX‐171‐003‐A1

Get full access to this article

View all access options for this article.

References

Hallek

Bergsagel

Anderson

. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998; 91: 3–21.

Laubach

Mitsiades

Mahindra

. Management of relapsed and relapsed/refractory multiple myeloma. J Natl Compr Canc Netw 2011; 9: 1209–1216.

Howlader N, Noone AM, Krapcho M, et al. SEER Stat Fact Sheets: Myeloma, http://seer.cancer.gov/statfacts/html/mulmy.html (accessed 19 July 2012).

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Multiple Myeloma Version 1.2012, http://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf (accessed 19 July 2012).

Kyle

Rajkumar

. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23: 3–9.

Rajkumar

Rosinol

Hussein

. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 2008; 26: 2171–2177.

San Miguel

Schlag

Khuageva

. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359: 906–917.

Cavo

Tacchetti

Patriarca

. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010; 376: 2075–2085.

Richardson

Weller

Lonial

. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010; 116: 679–686.

10.

Jung

Catalgol

Grune

. The proteasomal system. Mol Aspects Medicine 2009; 30: 191–296.

11.

Rock

Gramm

Rothstein

. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 1994; 78: 761–771.

12.

Kuhn

Chen

Voorhees

. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 2007; 110: 3281–3290.

13.

Parlati

Lee

Aujay

. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood 2009; 114: 3439–3447.

14.

Adams

. Proteasome inhibition: a novel approach to cancer therapy. Trends Mol Med 2002; 8: S49–S54.

15.

Van Waes

. Nuclear factor-kappaB in development, prevention, and therapy of cancer. Clin Cancer Res 2007; 13: 1076–1082.

16.

Adams

. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004; 4: 349–360.

17.

Obeng

Carlson

Gutman

. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006; 107: 4907–4916.

18.

Yang

Wang

Fang

. Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats. Drug Metab Dispos 2011; 39: 1873–1882.

19.

O'Connor

Stewart

Vallone

. A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res 2009; 15: 7085–7091.

20.

Badros

Vij

Martin

. Phase I Study of carfilzomib in patients (Pts) with relapsed and refractory multiple myeloma (MM) and varying degrees of renal insufficiency [abstract]. Blood (ASH Annual Meeting Abstracts) 2009; 114: 3877–3877.

21.

Alsina

Trudel

Vallone

. Phase 1 single agent antitumor activity of twice weekly consecutive day dosing of the proteasome inhibitor carfilzomib (PR-171) in hematologic malignancies [Abstract]. Blood (ASH Annual Meeting Abstracts) 2007; 110: 411–411.

22.

Siegel

Martin

Wang

. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 2012; 120: 2817–2825.

23.

Kyprolis (carfilzomib) [Package insert]. South San Francisco, CA: Onxyx Pharmaceuticals, Inc, 2012.

24.

Badros

Vij

Martin

. Phase II study of carfilzomib in patients with relapsed/refractory multiple myeloma and renal insufficiency [Abstract]. J Clin Oncol 2010; 28: 8128–8128.

25.

Jakubowiak

Dytfeld

Griffith

. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood 2012; 120: 1801–1809.

26.

ClinicalTrials.gov. A randomised, multicentre, phase 3 study comparing carfilzomib, lenalidomide, and dexamethasone (CRd), vs lenalidomide and dexamethasone (Rd) in subjects with relapsed multiple myeloma, http://clinicaltrials.gov/show/NCT01080391 (accessed 25 August 2012).

27.

ClinicalTrials.gov. A randomised, open-label, phase 3 study of carfilzomib plus dexamethasone vs bortezomib plus dexamethasone in patients with relapsed multiple myeloma, http://clinicaltrials.gov/show/NCT01568866 (accessed 25 August 2012).

28.

ClinicalTrials.gov. A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma, http://clinicaltrials.gov/show/NCT01302392 (accessed 25 August 2012).

29.

National Cancer Institute Common Terminology Criteria for Adverse Events v4.0. NCI, NIH, DHHS, 29 May 2009. NIH publication no. 09-7473 (accessed 11 August 2012).

Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma

Abstract

Purpose

Summary

Conclusion

Keywords

Get full access to this article

References